Veliparib dihydrochloride
Based on 51 publication(s) in Google Scholar
Veliparib (dihydrochloride) is a potent inhibitor of PARP1 and PARP2 with Kis of 5.2 nM and 2.9 nM in cell-free assays, respectively.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 912445-05-7
- Formula: C13H18Cl2N4O
- Molecular Weight:317.21
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Rare Diseases Drug Library
HY-L102
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Heterocyclic Compound Library
HY-L138
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
Publications Citing Use of MedChemExpress (MCE) Veliparib dihydrochloride
More- Nature. 2025 Sep;645(8082):1071-1080. [Abstract]
- Cancer Discov. 2017 Sep;7(9):984-998. [Abstract]
- Cancer Res. 2025 May 14. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
- Mol Cell. 2026 Apr 16;86(8):1427-1440.e5. [Abstract]
- Nat Chem Biol. 2025 Jun 27. [Abstract]
- Theranostics. 2020 Jul 25;10(21):9477-9494. [Abstract]
- Adv Sci (Weinh). 2025 Jul 16:e15585. [Abstract]
- Adv Sci (Weinh). 2025 Jun 25:e02448. [Abstract]
- Cell Death Dis. 2024 Dec 18;15(12):914. [Abstract]
- Cancer Genet. 2019 Nov:239:26-32. [Abstract]
- Clin Cancer Res. 2017 Feb 15;23(4):1001-1011. [Abstract]
- Acta Pharmacol Sin. 2022 Apr;43(4):781-787. [Abstract]
- J Transl Med. 2024 Nov 26;22(1):1062. [Abstract]
- Oncogene. 2022 Sep;41(37):4271-4281. [Abstract]
- Int J Biol Macromol. 2023 Jul 1;242(Pt 2):124794. [Abstract]
- Sci Signal. 2025 Oct 21;18(909):eadx2532. [Abstract]
- J Invest Dermatol. 2024 May 30:S0022-202X(24)00384-1. [Abstract]
- Mol Cancer Ther. 2019 Nov;18(11):2063-2073. [Abstract]
- Ecotoxicol Environ Saf. 2023 Mar 1:252:114630. [Abstract]
- Cells. 2021 Mar 9;10(3):599. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Neoplasia. 2025 May:63:101152. [Abstract]
- Cancers (Basel). 2024 Nov 5;16(22):3728. [Abstract]
- Cancers (Basel). 2024 Oct 10;16(20):3441. [Abstract]
- Nanomaterials. 2021 Jun 8;11(6):1514. [Abstract]
- Neoplasia. 2019 Apr 24;21(6):533-544. [Abstract]
- Neoplasia. 2018 Mar 28;20(5):478-488. [Abstract]
- Cell Signal. 2025 Jul:131:111709. [Abstract]
- Front Mol Biosci. 2021 Apr 29:8:633344. [Abstract]
- BMC Cancer. 2022 Mar 23;22(1):312. [Abstract]
- Analyst. 2025 Dec 1;150(24):5501-5513. [Abstract]
- Front Oncol. 2021 Jul 9:11:681441. [Abstract]
- Biomed Res Int. 2023 Feb 6:2023:7891753. [Abstract]
- FEBS Open Bio. 2025 Dec 5. [Abstract]
- EJNMMI Res. 2025 Apr 29;15(1):50. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Oct 1;1154:122195. [Abstract]
- Oncol Lett. 2025 Jan 7;29(3):128. [Abstract]
- J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. [Abstract]
- EANM Innovation. 2026 May 19;3:100274.
- bioRxiv. 2025 Nov 4:2025.11.03.686423. [Abstract]
- Research Square Preprint. 2024 Nov 06.
- Res Sq. 2024 Feb 21:rs.3.rs-3970470. [Abstract]
- Research Square Preprint. 2021 Feb.
- Patent. US20200129476A1
- Patent. US20200078369A1
- Patent. US20180362972A1.
- Patent. US20180263995A1.
- Int J Curr Res Acad Rev. 2017; 5(3): 53-64.
- Electrostatics Joint Conference. 2016 July.
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
WB
-
RT-PCR
-
Bio/Physico-chemical Assay
-
WB
Biological Activity
|
PARP-2 2.9 nM (Ki) |
PARP-1 5.2 nM (Ki) |
Veliparib is inactive to SIRT2 (>5 μM)[1]. Veliparib inhibits the PARP activity with EC50 of 2 nM in C41 cells[2]. Veliparib can decrease the PAR levels in both irradiated and nonirradiated H460 cells. Veliparib reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. Veliparib increases apoptosis and autophagy in H460 cells when combination with radiation[3]. Veliparib inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. Veliparib (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. Veliparib shows effective radiosensitivity in oxic H1299 cells. Veliparib can attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 912445-05-7
-
Appearance Solid
-
Molecular Weight 317.21
-
Formula C13H18Cl2N4O
-
Color White to off-white
-
SMILES
O=C(C1=C2NC([C@@]3(NCCC3)C)=NC2=CC=C1)N.Cl.Cl
-
Synonyms
ABT-888 dihydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (51)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Sep;645(8082):1071-1080. PMID: 40804522 -
Cancer Discov
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. [Abstract]2017 Sep;7(9):984-998. PMID: 28588062 -
Cancer Res
SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. [Abstract]2025 May 14. PMID: 40366633 -
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Nat Commun
2021 Jun 24;12(1):3931. PMID: 34168143
Veliparib dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
Veliparib (10 μM; 24 h). Immunoblots for STAT1a S727p in iBMDMs treated with IFNγ ± Veliparib (Vel.) as indicated.
Veliparib dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
Veliparib (10 μM; 24 h). Bar graphs showing the relative mRNA levels upon treatment IFNγ treatment ± Veliparib (Vel.).
Veliparib dihydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 24;12(1):3931. [Abstract]
Veliparib (10 μM; 24 h). PARP catalytic inhibition results in attenuation of NOS activity in iBMDMs. The cells were treated with IFNγ and Veliparib for 24 hours as indicated.
-
Mol Cell
2026 Apr 16;86(8):1427-1440.e5. PMID: 41935526 -
Nat Chem Biol
2025 Jun 27. PMID: 40579572 -
Theranostics
Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas. [Abstract]2020 Jul 25;10(21):9477-9494. PMID: 32863940 -
Adv Sci (Weinh)
Disruption of ARID1B Recruitment to the Nuclear Pore Complex as a New Anticancer Therapeutic Strategy. [Abstract]2025 Jul 16:e15585. PMID: 40671262
Veliparib dihydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Jul 16:e15585. [Abstract]
Veliparib (0-100 μM; 72 h). Dose‐response curves for Veliparib after 72 h of treatment in MDA‐MB‐468 cells comparing empty vector control (Control) and ARID1B OE cells.
-
Adv Sci (Weinh)
Combining PIM-2 and PARP1 Inhibitors Induces MICA Expression on Multiple Myeloma Cells to Activate NK Cells through NKG2D Binding. [Abstract]2025 Jun 25:e02448. PMID: 40557764 -
Cell Death Dis
Mitochondria-targeted oligomeric α-synuclein induces TOM40 degradation and mitochondrial dysfunction in Parkinson's disease and parkinsonism-dementia of Guam. [Abstract]2024 Dec 18;15(12):914. PMID: 39695091 -
Cancer Genet
A novel BRCA1 germline mutation promotes triple-negative breast cancer cells progression and enhances sensitivity to DNA damage agents. [Abstract]2019 Nov:239:26-32. PMID: 31476665 -
Clin Cancer Res
Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors. [Abstract]2017 Feb 15;23(4):1001-1011. PMID: 27559053 -
Acta Pharmacol Sin
2022 Apr;43(4):781-787. PMID: 34294887 -
J Transl Med
Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. [Abstract]2024 Nov 26;22(1):1062. PMID: 39587643 -
Oncogene
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. [Abstract]2022 Sep;41(37):4271-4281. PMID: 35933519 -
Int J Biol Macromol
Exploring the stabilizing effect on the i-motif of neighboring structural motifs and drugs. [Abstract]2023 Jul 1;242(Pt 2):124794. PMID: 37182626 -
Sci Signal
PARP1-mediated PARylation of TEAD4 stabilizes the YAP1-TEAD4 complex and promotes growth and immune evasion in breast cancer cells. [Abstract]2025 Oct 21;18(909):eadx2532. PMID: 41118450 -
J Invest Dermatol
TRPV3-Activated PARP1/AIFM1/MIF Axis through Oxidative Stress Contributes to Atopic Dermatitis. [Abstract]2024 May 30:S0022-202X(24)00384-1. PMID: 38823435 -
Mol Cancer Ther
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation. [Abstract]2019 Nov;18(11):2063-2073. PMID: 31413177 -
Ecotoxicol Environ Saf
PARP1 promotes NLRP3 activation via blocking TFEB-mediated autophagy in rotenone-induced neurodegeneration. [Abstract]2023 Mar 1:252:114630. PMID: 36764072 -
Cells
New Insights into the Significance of PARP-1 Activation: Flow Cytometric Detection of Poly(ADP-Ribose) as a Marker of Bovine Intramammary Infection. [Abstract]2021 Mar 9;10(3):599. PMID: 33803196 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Neoplasia
Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. [Abstract]2025 May:63:101152. PMID: 40096771 -
Cancers (Basel)
2024 Nov 5;16(22):3728. PMID: 39594684 -
Cancers (Basel)
Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors. [Abstract]2024 Oct 10;16(20):3441. PMID: 39456536 -
Nanomaterials
Co-Encapsulation of Methylene Blue and PARP-Inhibitor into Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Enhanced PDT of Cancer. [Abstract]2021 Jun 8;11(6):1514. PMID: 34201069 -
Neoplasia
DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors. [Abstract]2019 Apr 24;21(6):533-544. PMID: 31029033 -
Neoplasia
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. [Abstract]2018 Mar 28;20(5):478-488. PMID: 29605721 -
Cell Signal
2025 Jul:131:111709. PMID: 40037423 -
Front Mol Biosci
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma. [Abstract]2021 Apr 29:8:633344. PMID: 33996894 -
BMC Cancer
PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth. [Abstract]2022 Mar 23;22(1):312. PMID: 35321693 -
Analyst
Determination of veliparib metabolic stability in the human liver microsomes using a hydrophilic interaction UPLC-MS/MS quantitative method: greenness assessment with an in silico study for ADME, DEREK alarms and metabolic lability. [Abstract]2025 Dec 1;150(24):5501-5513. PMID: 41231074 -
Front Oncol
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma. [Abstract]2021 Jul 9:11:681441. PMID: 34307148 -
Biomed Res Int
ATR Inhibitor Synergizes PARP Inhibitor Cytotoxicity in Homologous Recombination Repair Deficiency TK6 Cell Lines. [Abstract]2023 Feb 6:2023:7891753. PMID: 36794257 -
FEBS Open Bio
Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [Abstract]2025 Dec 5. PMID: 41347713 -
EJNMMI Res
Evaluation of a simplified radiolabeling method for a PARP inhibitor in an animal model of breast cancer. [Abstract]2025 Apr 29;15(1):50. PMID: 40301197 -
J Chromatogr B Analyt Technol Biomed Life Sci
Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study. [Abstract]2020 Oct 1;1154:122195. PMID: 32943176 -
Oncol Lett
DNA damage response mutations enhance the antitumor efficacy of ATR and PARP inhibitors in cholangiocarcinoma cell lines. [Abstract]2025 Jan 7;29(3):128. PMID: 39822940 -
J Vet Med Sci
2018 Nov 23;80(11):1775-1781. PMID: 30249935
Veliparib dihydrochloride purchased from MedChemExpress. Usage Cited in: J Vet Med Sci. 2018 Nov 23;80(11):1775-1781. [Abstract]
PK-15 cells are incubated with 20 μM ABT-888 for 1 hr and subsequently infected with transmissible gastroenteritis virus (TGEV) for 36 hr. Cells are collected and then subjected to Western blot analysis for PARP-1.
-
-
bioRxiv
Design and Development of DNA Damage Chemical Inducers of Proximity (DD-CIP) for Targeted Cancer Therapy. [Abstract]2025 Nov 4:2025.11.03.686423. PMID: 41278667 -
-
Res Sq
Mitochondria-Targeted Oligomeric α-Synuclein Induces TOM40 Degradation and Mitochondrial Dysfunction in Parkinson's Disease and Parkinsonism-Dementia of Guam. [Abstract]2024 Feb 21:rs.3.rs-3970470. PMID: 38464024 -
-
-
-
-
-
-
Solvent & Solubility
H2O : 250 mg/mL (788.12 mM; Need ultrasonic)
DMSO : ≥ 3.2 mg/mL (10.09 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (315.25 mM); Clear solution; Need ultrasonic
Protocol
PARP assays are conducted in a buffer containing 50 mM Tris (pH 8.0), 1 mM DTT, 1.5 μM [3H]NAD+ (1.6 μCi/mmol), 200 nM biotinylated histone H1, 200 nM slDNA, and 1 nM PARP-1 or 4 nM PARP-2 enzyme. Reactions are terminated with 1.5 mM benzamide, transferred to streptavidin Flash plates, and counted using a TopCount microplate scintillation counter.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
For B16F10 syngeneic studies, 6×104 cells are mixed with 50% Matrigel and inoculated by s.c. injection into the flank of 6- to 8-week-old female C57BL/6 mice (20 g). For cisplatin efficacy studies, female nude mice are implanted s.c. by trocar with fragments (20-30 mm3) of human tumors harvested from s.c. grown tumors in nude mice hosts. For the carboplatin and MX-1 cyclophosphamide studies, female scid mice are inoculated with 200 μL of a 1:10 dilution of tumor brei in 45% Matrigel and 45% Spinner MEM. For these established tumor studies, tumors are allowed to grow to the indicated size and then randomized to therapy groups. For DOHH-2 xenograft studies, 1×106 cells are mixed with 50% Matrigel and inoculated by s.c. injection into the flank of male scid mice. Veliparib is delivered by either oral route or continuous infusion using s.c. placement of 14-day Alzet OMP model 2002 in a vehicle containing 0.9% NaCl adjusted to pH 4.0. The OMP delivers at a rate of 12 μL daily and Veliparib doses are calculated accordingly. Temozolomide, cisplatin, carboplatin, and cyclophosphamide are formulated according to the manufacturers' recommendations.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Donawho CK, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res. 2007 May 1;13(9):2728-37. [Content Brief]
[2]. Penning TD, et al. Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem. 2009 Jan 22;52(2):514-23. [Content Brief]
[3]. Albert JM, et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res. 2007 May 15;13(10):3033-42. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 3.1525 mL | 15.7624 mL | 31.5249 mL | 78.8121 mL |
| 5 mM | 0.6305 mL | 3.1525 mL | 6.3050 mL | 15.7624 mL | |
| 10 mM | 0.3152 mL | 1.5762 mL | 3.1525 mL | 7.8812 mL | |
| H2O | 15 mM | 0.2102 mL | 1.0508 mL | 2.1017 mL | 5.2541 mL |
| 20 mM | 0.1576 mL | 0.7881 mL | 1.5762 mL | 3.9406 mL | |
| 25 mM | 0.1261 mL | 0.6305 mL | 1.2610 mL | 3.1525 mL | |
| 30 mM | 0.1051 mL | 0.5254 mL | 1.0508 mL | 2.6271 mL | |
| 40 mM | 0.0788 mL | 0.3941 mL | 0.7881 mL | 1.9703 mL | |
| 50 mM | 0.0630 mL | 0.3152 mL | 0.6305 mL | 1.5762 mL | |
| 60 mM | 0.0525 mL | 0.2627 mL | 0.5254 mL | 1.3135 mL | |
| 80 mM | 0.0394 mL | 0.1970 mL | 0.3941 mL | 0.9852 mL | |
| 100 mM | 0.0315 mL | 0.1576 mL | 0.3152 mL | 0.7881 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Veliparib dihydrochloride Related Classifications
HY-10130 Related Classifications
Powered by Bioz